Equity Overview
Price & Market Data
Price: $0.718
Daily Change: +$0.0284 / 3.95%
Range: $0.469 - $0.755
Market Cap: $24,472,166
Volume: 5,825,932
Performance Metrics
1 Week: 152.5%
1 Month: 130.1%
3 Months: 94.03%
6 Months: -79.69%
1 Year: -80.95%
YTD: 41.79%
Company Details
Employees: 17
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial in patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company is headquartered in Coral Gables, Florida.